Trade Q32 Bio Inc - QTTB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0758 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.0971 |
| Open | 2.0771 |
| 1-Year Change | 127.65% |
| Day's Range | 1.9871 - 2.0771 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 2.0971 | 0.3300 | 18.67% | 1.7671 | 2.1371 | 1.7671 |
| Apr 16, 2025 | 1.8071 | -0.1300 | -6.71% | 1.9371 | 1.9371 | 1.7871 |
| Apr 15, 2025 | 1.9771 | 0.1000 | 5.33% | 1.8771 | 2.0171 | 1.8771 |
| Apr 14, 2025 | 1.8771 | -0.1500 | -7.40% | 2.0271 | 2.0271 | 1.8271 |
| Apr 11, 2025 | 2.0171 | 0.3700 | 22.46% | 1.6471 | 2.0571 | 1.6471 |
| Apr 10, 2025 | 1.6271 | -0.0200 | -1.21% | 1.6471 | 1.6771 | 1.5171 |
| Apr 9, 2025 | 1.6371 | 0.2100 | 14.72% | 1.4271 | 1.7071 | 1.3571 |
| Apr 8, 2025 | 1.4171 | -0.0900 | -5.97% | 1.5071 | 1.5371 | 1.3571 |
| Apr 7, 2025 | 1.4971 | 0.0100 | 0.67% | 1.4871 | 1.6771 | 1.4071 |
| Apr 4, 2025 | 1.6071 | 0.0700 | 4.55% | 1.5371 | 1.7471 | 1.5271 |
| Apr 3, 2025 | 1.5871 | 0.1600 | 11.21% | 1.4271 | 1.7571 | 1.3871 |
| Apr 2, 2025 | 1.4671 | 0.0100 | 0.69% | 1.4571 | 1.5471 | 1.4471 |
| Apr 1, 2025 | 1.4671 | -0.1400 | -8.71% | 1.6071 | 1.6071 | 1.4671 |
| Mar 31, 2025 | 1.6371 | -0.0600 | -3.54% | 1.6971 | 1.6971 | 1.5271 |
| Mar 28, 2025 | 1.6771 | -0.1700 | -9.20% | 1.8471 | 1.8471 | 1.6771 |
| Mar 27, 2025 | 1.8871 | -0.0300 | -1.56% | 1.9171 | 2.0071 | 1.8571 |
| Mar 26, 2025 | 1.9471 | -0.0800 | -3.95% | 2.0271 | 2.0271 | 1.9371 |
| Mar 25, 2025 | 2.0271 | -0.0800 | -3.80% | 2.1071 | 2.1071 | 1.9871 |
| Mar 24, 2025 | 2.1471 | 0.0600 | 2.87% | 2.0871 | 2.1471 | 2.0371 |
| Mar 21, 2025 | 2.0071 | -0.0400 | -1.95% | 2.0471 | 2.0771 | 1.9971 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Homology Medicines Company profile
About Homology Medicines Inc
Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).
| Industry: | Bio Therapeutic Drugs |
1 Patriots Park
BEDFORD
MASSACHUSETTS 01730-2343
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com